Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Choueiri Discusses the CANTATA Trial in RCC

Toni Choueiri, MD
Published: Thursday, Oct 04, 2018



Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CANTATA trial in renal cell carcinoma (RCC).

CANTATA (NCT03428217) is a trial in progress that is comparing cabozantinib (Cabometyx) plus CB-839 with cabozantinib plus placebo in patients with metastatic RCC. This is an international, double-blind, placebo-controlled, randomized phase II study with a primary endpoint of progression-free survival and a secondary endpoint of overall survival. Patients in the experimental arm will receive oral CB-839 twice daily plus oral cabozantinib twice daily.

Choueiri says that CB-839 is an important emerging agent in RCC, as well as other tumors. Cabozantinib was approved by the FDA in December 2017 for previously untreated patients with advanced RCC. The combination of the oral glutaminase inhibitor CB-839 with a standard drug like cabozantinib makes sense, says Choueiri, adding that CANTATA is an important study to follow.


Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CANTATA trial in renal cell carcinoma (RCC).

CANTATA (NCT03428217) is a trial in progress that is comparing cabozantinib (Cabometyx) plus CB-839 with cabozantinib plus placebo in patients with metastatic RCC. This is an international, double-blind, placebo-controlled, randomized phase II study with a primary endpoint of progression-free survival and a secondary endpoint of overall survival. Patients in the experimental arm will receive oral CB-839 twice daily plus oral cabozantinib twice daily.

Choueiri says that CB-839 is an important emerging agent in RCC, as well as other tumors. Cabozantinib was approved by the FDA in December 2017 for previously untreated patients with advanced RCC. The combination of the oral glutaminase inhibitor CB-839 with a standard drug like cabozantinib makes sense, says Choueiri, adding that CANTATA is an important study to follow.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x